<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part5">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>5</PartID>
        <PartNumber>Part IV</PartNumber>
        <PartSequenceNumber>5</PartSequenceNumber>
        <PartTitle>Bone Metastasis</PartTitle>
        <PartChapterCount>5</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap24" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>24</ChapterID>
          <ChapterNumber>Chapter 24</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_24</ChapterDOI>
          <ChapterSequenceNumber>24</ChapterSequenceNumber>
          <ChapterTitle Language="En">Bisphosphonates for Prevention and Treatment of Bone Metastases</ChapterTitle>
          <ChapterFirstPage>267</ChapterFirstPage>
          <ChapterLastPage>275</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>5</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff1_24" CorrespondingAffiliationID="Aff1_24">
              <AuthorName DisplayOrder="Western">
                <GivenName>Philip</GivenName>
                <GivenName>J.</GivenName>
                <FamilyName>Saylor</FamilyName>
              </AuthorName>
              <Contact>
                <Email>psaylor@partners.org</Email>
              </Contact>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Matthew</GivenName>
                <GivenName>R.</GivenName>
                <FamilyName>Smith</FamilyName>
              </AuthorName>
            </Author>
            <Affiliation ID="Aff1_24">
              <OrgDivision>Department of Medicine, Division of Hematology/Oncology</OrgDivision>
              <OrgName>Massachusetts General Hospital Cancer Center</OrgName>
              <OrgAddress>
                <City>Boston</City>
                <State>MA</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_24" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Most men with advanced prostate cancer develop bone metastases. The most common sites of bone metastases from prostate cancer are the spine, pelvis, and ribs. Though they typically have a sclerotic or osteoblastic appearance when imaged, these metastases feature excess activity by both osteoblasts and osteoclasts. Pathologic osteoclast activation is associated with skeletal complications, disease progression, and death. The clinical burden of bone metastases is high as they commonly present with pain but can also present with spinal cord compression, fractures, and myelophthisis.</Para>
            <Para TextBreak="No">Zoledronic acid is a potent intravenous bisphosphonate. In men with castration-resistant prostate cancer and bone metastases, zoledronic acid decreases the risk of disease-related skeletal complications. There is limited information about the optimal frequency and duration of therapy for men with castration-resistant disease and bone metastases. The role of zoledronic acid and other bisphosphonates in androgen-sensitive disease or for prevention of bone metastases is unknown. Further clinical trials are needed to establish its optimal frequency, dose, and duration of therapy.</Para>
            <Para TextBreak="No">Denosumab is a fully human monoclonal antibody against receptor activator of nuclear factor-kappa-B ligand (RANKL). Denosumab is currently under investigation in three major prostate cancer trials that are designed to evaluate its ability to prevent fractures, bone metastases, and disease-related skeletal events.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Prostate cancer</Keyword>
            <Keyword>Bone metastases</Keyword>
            <Keyword>Osteoclast</Keyword>
            <Keyword>Bisphosphonate</Keyword>
            <Keyword>Skeletal-related events</Keyword>
            <Keyword>Denosumab</Keyword>
            <Keyword>Odanacatib</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1">
            <Heading>Normal Bone Physiology</Heading>
            <Para TextBreak="No">Healthy bone is maintained by a dynamic and ongoing process of remodeling throughout the skeleton. This process depends on a balance between bone resorption by osteoclasts and new bone formation by osteoblasts. Osteoclasts are tissue-specific macrophages that grow and differentiate from monocyte/macrophage progenitors. Osteoclasts resorb bone by binding to it and creating a sealed resorption vacuole into which they secrete protons and lytic enzymes. The two most active enzymes within this acidified compartment are tartrate-resistant acid phosphatase (TRAP) and cathepsin [<CitationRef CitationID="CR1_24">1</CitationRef>].</Para>
            <Para TextBreak="No">The receptor activator of nuclear factor-kappa-B (RANK) signaling pathway is central to regulation of both immature and mature osteoclasts, though at least 24 additional genes or loci have been shown to be involved in osteoclast regulation. The pathway consists of RANK ligand (RANKL) and its two receptors: RANK and osteoprotegerin. Osteoprotegerin competitively inhibits RANK activation by acting as a decoy receptor for RANKL. Activation of RANK by RANKL on the surface of osteoclast precursors leads to gene expression and cellular differentiation to mature multinucleated osteoclasts. Similar RANK activation on mature osteoclasts leads to longer survival and an increase in bone resorption.</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Pathophysiology of Osteoblastic Bone Metastases</Heading>
            <Para TextBreak="No">Bone biopsies in men with metastatic prostate cancer show evidence of a high turnover state with activation of both osteoclasts and osteoblasts in the areas involved with tumor. As osteoclasts erode normal trabecular bone, osteoblasts replace it with sclerotic woven bone. Though woven bone characteristically appears dense or blastic when imaged, such blastic metastases considerably weaken the structural integrity of the bone and increase fracture risk [<CitationRef CitationID="CR2_24">2</CitationRef>].</Para>
            <Para TextBreak="No">Several urine and serum laboratory markers are elevated in the presence of bone metastases as a reflection of bone resorption and formation. Urinary N-telopeptide (NTx) is a marker of collagen breakdown by osteoclasts. Bone-specific alkaline phosphatase (BAP) is a marker of osteoblast function. Both NTx and BAP have been found to be significantly elevated in patients with bone metastases from prostate cancer [<CitationRef CitationID="CR3_24">3</CitationRef>]. Correlation between serum alkaline phosphatase (AP) and BAP is strong, making the more available AP a practical alternative to measuring the bone-specific isoform [<CitationRef CitationID="CR4_24">4</CitationRef>].</Para>
            <Para TextBreak="No">These lab tests can be used to estimate prognosis and monitor response to therapy. Binary (high vs. low) classification of resorption (NTx) and formation (BAP) markers in patients with solid tumors metastatic to bone has demonstrated that high initial levels correlate with adverse outcomes such as skeletal-related events, clinical bone disease progression, and death. Markers of resorption fall substantially in response to osteoclast inhibition or to RANKL inhibition [<CitationRef CitationID="CR5_24">5</CitationRef>]. Bone metabolism markers have been used to guide decisions about dose and schedule selection in early phase clinical trials but are not yet used to make treatment decisions in routine clinical practice.</Para>
          </Section1>
          <Section1 ID="Sec3">
            <Heading>Clinical Manifestations of Bone Metastases</Heading>
            <Para TextBreak="No">Pain is easily the most frequent clinical manifestation of bone metastases, though they can also cause fractures or spinal cord compression. Androgen deprivation therapy (ADT), the mainstay of treatment for metastatic prostate cancer, accelerates bone turnover [<CitationRef CitationID="CR6_24">6</CitationRef>, <CitationRef CitationID="CR7_24">7</CitationRef>], decreases bone mineral density (BMD) [<CitationRef CitationID="CR6_24">6</CitationRef>–<CitationRef CitationID="CR11_24">11</CitationRef>], and contributes to fracture risk [<CitationRef CitationID="CR12_24">12</CitationRef>–<CitationRef CitationID="CR14_24">14</CitationRef>]. Fracture is most common in the vertebral bodies but can also be observed in the pelvis, ribs, or long bones. Hypocalcemia due to calcium deposition in newly formed bone is common but is usually asymptomatic. Finally, androgen deprivation routinely causes a mild normocytic anemia [<CitationRef CitationID="CR15_24">15</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec4">
            <Heading>Bisphosphonates</Heading>
            <Para TextBreak="No">Bisphosphonates are chemically similar to inorganic pyrophosphate, a necessary component of normal bone [<CitationRef CitationID="CR16_24">16</CitationRef>]. A central carbon binds to the two phosphate groups and to the two organic side chains that identify each particular bisphosphonate. Their therapeutic benefits seem to stem from a combination of this affinity for bone and their effects on the osteoclasts themselves.</Para>
            <Para TextBreak="No">The negatively charged phosphate groups have strong affinity for cations such as calcium and therefore are easily incorporated into bone, though the strength of this affinity varies considerably from one bisphosphonate to the next. Bisphosphonates are chemically resistant to hydrolysis and exert potent inhibitory and even proapoptotic effects on the osteoclasts that encounter them at highest concentration and ingest them by endocytosis [<CitationRef CitationID="CR17_24">17</CitationRef>]. Nitrogen-containing bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid) inhibit farnesyl pyrophosphate synthase, a branch-point enzyme in the mevalonate pathway that is important to osteoclast function, though other cellular pathways are likely involved [<CitationRef CitationID="CR18_24">18</CitationRef>].</Para>
            <Para TextBreak="No">Potency of osteoclast inhibition can be estimated by farnesyl pyrophosphate synthase inhibition, a property that orders the available bisphosphonates as follows: etidronate = clodronate &lt;&lt;&lt; pamidronate &lt; alendronate &lt; ibandronate &lt; risedronate &lt; zoledronic acid [<CitationRef CitationID="CR18_24">18</CitationRef>]. Zoledronic acid is the most potent of the available bisphosphonates, at least 100 times more potent than clodronate or pamidronate in preclinical models.</Para>
          </Section1>
          <Section1 ID="Sec5">
            <Heading>Bisphosphonates in Metastatic Bone Disease</Heading>
            <Para TextBreak="No">In 1995, pamidronate was approved by the Food and Drug Administration to prevent disease-related skeletal complications in patients with bone metastases from breast cancer and bone disease from multiple myeloma. In 2002, zoledronic acid was approved for the prevention of skeletal complications in patients with myeloma bone disease and bone metastases from solid tumors including breast, lung, and prostate cancer. This approval of zoledronic acid was based on the results of three large randomized controlled trials that included over 3,000 patients with a variety of malignancies [<CitationRef CitationID="CR19_24">19</CitationRef>–<CitationRef CitationID="CR21_24">21</CitationRef>]. In prostate cancer specifically, it was shown to reduce skeletal-related events (SREs) in the setting of castration-resistant metastatic disease [<CitationRef CitationID="CR21_24">21</CitationRef>]. Zoledronic acid is not approved for treatment of hormone-sensitive metastatic disease or for treatment of men without bone metastases.</Para>
          </Section1>
          <Section1 ID="Sec6">
            <Heading>Bisphosphonates in the Treatment of Castration-Resistant Prostate Cancer</Heading>
            <Para TextBreak="No">In the USA, zoledronic acid is approved for the prevention of SREs in men with prostate cancer and bone metastases who have failed first line hormone therapy (castration-resistant metastatic disease). The Zometa 039 study established its efficacy in this setting where comparably designed trials with pamidronate and clodronate had failed to demonstrate benefit (Table <InternalRef RefID="Tab1">24.1</InternalRef>).<Table Float="Yes" ID="Tab1">
                <Caption Language="En">
                  <CaptionNumber>Table 24.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Notable randomized controlled trials using bisphosphonates for metastatic prostate cancer</SimplePara>
                  </CaptionContent>
                </Caption>
                <tgroup cols="5">
                  <colspec colname="c1" colnum="1"/>
                  <colspec colname="c2" colnum="2"/>
                  <colspec colname="c3" colnum="3"/>
                  <colspec colname="c4" colnum="4"/>
                  <colspec colname="c5" colnum="5"/>
                  <thead>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Study</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>
                          <Emphasis Type="Italic">n</Emphasis>
                        </SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Study population</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Arms</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Outcome</SimplePara>
                      </entry>
                    </row>
                  </thead>
                  <tbody>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Zometa 039</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>643</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Asymptomatic or minimally symptomatic, castration-resistant</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Zoledronic acid vs. placebo, every 3 weeks</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Significant decrease in skeletal-related events, trend toward improved survival</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Study 032/INT</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>350</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Symptomatic, castration-resistant</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Pamidronate vs. placebo, every 3 weeks</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>No significant difference in pain, analgesic use, or skeletal-related events</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>NCIC Pr06</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>204</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Symptomatic, castration-resistant</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Mitoxantrone and prednisone ± clodronate, every 3 weeks IV</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>No significant difference in palliative response (pain scores or analgesic use)</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>MRC Pr05</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>311</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Androgen-sensitive</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Daily oral clodronate vs. placebo</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Trend toward improved bone progression-free survival (<Emphasis Type="Italic">P</Emphasis>= 0.066)</SimplePara>
                      </entry>
                    </row>
                  </tbody>
                </tgroup>
              </Table>
            </Para>
            <Para TextBreak="No">Zometa 039 was a randomized, placebo controlled trial that enrolled 643 patients with castration-resistant prostate cancer and asymptomatic or minimally symptomatic bone metastases. Subjects were randomized to placebo or to one of two doses of zoledronic acid (4 or 8 mg every 3 weeks for 15 months). Primary therapy for the prostate cancer was as chosen by the treating physicians, and androgen deprivation was continued throughout. The primary efficacy endpoint was the proportion of patients who experienced at least one SRE during the study period. SREs included pathologic bone fractures, spinal cord compression, surgery or radiation to bone, and antineoplastic therapy to treat bone pain [<CitationRef CitationID="CR21_24">21</CitationRef>].</Para>
            <Para TextBreak="No">Though the trial began with two-dose cohorts for zoledronic acid, concern about renal toxicity led to two protocol modifications prior to completion. First, the infusion time was lengthened from 5 to 15 min. Second, the 8-mg group was dose reduced to 4 mg. Of the 643 patients enrolled, 14 experienced grade 3 serum increases in creatinine (7 in the 4-mg group, 5 in the 8/4-mg group, 2 in the placebo group); none required dialysis.</Para>
            <Para TextBreak="No">At the 15-month conclusion of the trial, patients treated with 4-mg zoledronic acid had fewer SREs (33.2%) than patients who received placebo (44.2%) (<Emphasis Type="Italic">P</Emphasis>= 0.02). See Fig. <InternalRef RefID="Fig1">24.1</InternalRef> for a combined analysis of SRE prevention in this trial and another similar trial. Zoledronic acid treatment at 4 mg also lengthened median time to first SRE from 321 to 488 days (<Emphasis Type="Italic">P</Emphasis> = 0.009) [<CitationRef CitationID="CR22_24">22</CitationRef>]. Though the study was not designed to assess differences in overall survival, there was a nonsignificant improvement in median survival from 464 to 546 days (<Emphasis Type="Italic">P</Emphasis> = 0.091) in the 4-mg group compared with placebo. Follow-up at 24 months showed durable benefit as the risk of SREs was reduced by 36% compared with placebo (<Emphasis Type="Italic">P</Emphasis> = 0.002) [<CitationRef CitationID="CR22_24">22</CitationRef>]. This trial led to the approval of zoledronic acid for the treatment of castration-resistant prostate cancer metastatic to bone.<Figure Category="Standard" Float="Yes" ID="Fig1">
                <Caption Language="En">
                  <CaptionNumber>Fig. 24.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Cumulative incidence of skeletal-related events [<CitationRef CitationID="CR28_24">28</CitationRef>] The survival-adjusted cumulative incidence of skeletal-related events was significantly reduced by 35.3% by treatment with 4-mg zoledronic acid compared with placebo in two large prospective randomized controlled trials [<CitationRef CitationID="CR20_24">20</CitationRef>, <CitationRef CitationID="CR21_24">21</CitationRef>]</SimplePara>
                  </CaptionContent>
                </Caption>
                <MediaObject ID="MO1_24">
                  <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-829-4_24_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                </MediaObject>
              </Figure>
            </Para>
            <Para TextBreak="No">Combined analysis was performed on two multicenter, randomized, placebo-controlled trials (Protocol 032 and INT 05) that evaluated pamidronate (90 mg given intravenously every 3 weeks for 27 weeks). Together, the trials enrolled 350 patients. Efficacy was assessed with self-reported pain score, analgesic use, and proportion of patients with a SRE. There were no statistically significant differences in these endpoints between the treatment and placebo groups. Urinary bone resorption markers did decline with treatment, though less so than has typically been observed with zoledronic acid treatment. For example, NTx levels fell approximately 50% from baseline with pamidronate treatment but fell by more than 70% on treatment in the Zometa 039 study. Lack of pamidronate efficacy in this study may be at least partially due to less potent osteoclast inhibition [<CitationRef CitationID="CR23_24">23</CitationRef>].</Para>
            <Para TextBreak="No">The National Cancer Institute of Canada Pr06 (NCIC Pr06) evaluated patients with castration-resistant prostate cancer and symptomatic bone metastases. They were randomized in this double-blind, controlled trial to mitoxantrone and prednisone with or without the addition of clodronate (1,500 mg intravenously every 3 weeks). Mitoxantrone was given 12 mg/m<Superscript>2</Superscript> intravenously every 3 weeks and prednisone was given 5 mg twice daily. The primary endpoint was palliative response, defined as either a two-point pain reduction by the present pain intensity index or a 50% decrease in analgesic use. The majority (77%) of the 209 patients had mild pain scores at baseline. There was no statistically significant difference in achievement of the primary endpoint between the study group (46%) and the control group (39%) (<Emphasis Type="Italic">P</Emphasis> = 0.54). Secondary endpoints such as survival, quality of life, and progression-free survival (PFS) were also statistically unchanged between the groups [<CitationRef CitationID="CR24_24">24</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec7">
            <Heading>Bisphosphonates in the Treatment of Androgen-Sensitive Prostate Cancer</Heading>
            <Para TextBreak="No">The only completed trial to examine bisphosphonates in androgen-sensitive prostate cancer is the MRC PR05 trial that compared oral sodium clodronate (2,080 mg/day) to placebo for men with bone metastases. It was a double-blind, placebo-controlled trial and enrolled 311 patients for a maximum of 3 years of study-directed treatment. The primary endpoint was symptomatic bone PFS. Symptomatic bone PFS is a similar endpoint to SREs but requires that the event be clinically appreciated rather than simply an imaging finding. Overall survival was a secondary endpoint. After a median of 59 months, the treatment group showed nonsignificant improvements in overall survival (HR 0.80, 95% CI 0.62–1.03, <Emphasis Type="Italic">P</Emphasis> = 0.082) and in symptomatic bone PFS (HR 0.79, 95% CI 0.61–1.02, <Emphasis Type="Italic">P</Emphasis> = 0.066). Patients in the treatment group had a higher incidence of gastrointestinal adverse events (HR 1.71, 95% CI 1.21–2.41; <Emphasis Type="Italic">P</Emphasis> = 0.002) [<CitationRef CitationID="CR25_24">25</CitationRef>]. Interestingly, subgroup analysis suggested that earlier start of this therapy improved efficacy.</Para>
            <Para TextBreak="No">CALGB/CTSU 90202 is a currently enrolling randomized, double-blind, placebo-controlled phase III trial comparing early to standard zoledronic acid for the prevention of SREs in men with androgen-sensitive prostate cancer metastatic to bone. All patients are started on zoledronic acid within 3 months of initiation of androgen deprivation. This will be an important trial as it is well designed and examines a high risk but previously understudied population (hormone sensitive) while making use of a more potent bisphosphonate than was used in the MRC PR05 trial. The goal accrual is 680 patients.</Para>
          </Section1>
          <Section1 ID="Sec8">
            <Heading>Bisphosphonates for the Prevention of Bone Metastases</Heading>
            <Para TextBreak="No">Two randomized controlled trials have evaluated bisphosphonates for prevention of bone metastases in prostate cancer; neither showed significant benefit.</Para>
            <Para TextBreak="No">First, the Medical Research Council Pr04 trial enrolled 508 men with nonmetastatic prostate cancer and randomized them to daily oral clodronate (2,080 mg/daily) or to placebo for a maximum of 5 years. The patients were followed for a median of nearly 10 years. All men had locally advanced (T2–T4) prostate cancer and a negative bone scan at enrollment. The treatment group showed no sign of benefit. There was a nonsignificant increase in new bone metastases (80 events with clodronate, 68 events with placebo; HR = 1.22; 95% CI 0.88–1.68) and no change in overall survival (130 deaths with clodronate and 127 deaths with placebo, HR = 1.02, 95% CI = 0.80–1.30). Clodronate was well tolerated with only mild increases in gastrointestinal problems and increased lactate dehydrogenase levels [<CitationRef CitationID="CR26_24">26</CitationRef>]. Though the trial was well designed and follow-up was excellent, it was likely hurt by the use of clodronate, a comparatively weak bisphosphonate.</Para>
            <Para TextBreak="No">Second, Zometa 704 was designed to evaluate the ability of zoledronic acid to delay the time to first bone metastasis in patients with castration-resistant prostate cancer. Progression during ADT prior to study enrollment was defined as three consecutive rises in PSA at least 2 weeks apart from one another, initial PSA rise within 10 months of study entry, or last PSA at least 150% of the nadir value. Subjects were randomized to either zoledronic acid (4 mg intravenously every 4 weeks) or to placebo. Unfortunately, the study was placed on hold in September 2002 due to low event rate after accruing 398 of the planned 991 patients. It was eventually terminated. The study and control groups had similar time to first metastases but the low event rate and the low accrual both conspired against thorough evaluation.</Para>
            <Para TextBreak="No">Though the Zometa 704 trial was ended early, analysis of the 201 patients in the placebo group did yield interesting information about the natural history of PSA-only recurrent prostate cancer. Median bone metastasis-free survival was 30 months, and at 2-year follow-up 33% of patients had developed a bone metastasis. The most powerful predictors of time to first metastasis and overall survival were baseline PSA (if &gt;10 ng/mL, relative risk 3.18) and PSA velocity. Median time to first bone metastasis and overall survival had not been reached [<CitationRef CitationID="CR27_24">27</CitationRef>].</Para>
            <Para TextBreak="No">Though results of both trials were disappointing, they have strongly influenced the design of subsequent studies. The low event rate and long metastasis-free survival, even with castration-resistant prostate cancer, have led investigators to plan for higher enrollment and longer follow-up to achieve adequate statistical power. As an example, the three current denosumab trials (Table <InternalRef RefID="Tab2">24.2</InternalRef>) are planned to accrue over 4,500 patients in all.<Table Float="Yes" ID="Tab2">
                <Caption Language="En">
                  <CaptionNumber>Table 24.2</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Current randomized controlled trials of denosumab for prostate cancer</SimplePara>
                  </CaptionContent>
                </Caption>
                <tgroup cols="5">
                  <colspec colname="c1" colnum="1"/>
                  <colspec colname="c2" colnum="2"/>
                  <colspec colname="c3" colnum="3"/>
                  <colspec colname="c4" colnum="4"/>
                  <colspec colname="c5" colnum="5"/>
                  <thead>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Study/purpose</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>
                          <Emphasis Type="Italic">n</Emphasis>
                        </SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Study population</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Arms</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Endpoint(s)</SimplePara>
                      </entry>
                    </row>
                  </thead>
                  <tbody>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Amgen protocol 138: fracture prevention</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>1,468</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Current androgen deprivation therapy; no metastases</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Denosumab vs. placebo</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Incident vertebral fractures, bone mineral density</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Amgen protocol 147: metastasis prevention</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>1,400</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Castration-resistant, high risk but no bone metastases</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Denosumab vs. placebo</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Bone metastasis-free survival</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Amgen protocol 103: prevention of skeletal complications</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>1,700</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Castration-resistant, bone metastases</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Denosumab vs. zoledronic acid</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Skeletal-related events</SimplePara>
                      </entry>
                    </row>
                  </tbody>
                </tgroup>
              </Table>
            </Para>
          </Section1>
          <Section1 ID="Sec9">
            <Heading>Bisphosphonates: Safety</Heading>
            <Para TextBreak="No">Current clinical trial evidence supports the use of zoledronic acid (4 mg intravenously every 3–4 weeks) to reduce the risk of SREs in men with castration-resistant prostate cancer and bone metastases [<CitationRef CitationID="CR28_24">28</CitationRef>]. Androgen-sensitive disease is an area of ongoing investigation and is currently without clear evidence to support bisphosphonate treatment. Widespread and increasingly long courses of bisphosphonate treatment have led to a better understanding of their toxicities.</Para>
            <Para TextBreak="No">The two most common side effects of bisphosphonate therapy are an acute phase reaction and hypocalcemia. This acute phase reaction is generally a self-limited flu-like illness that starts within a day of the infusion and may include nausea/vomiting and fever [<CitationRef CitationID="CR29_24">29</CitationRef>]. Calcium and vitamin D supplementation are recommended during bisphosphonate treatment to prevent symptomatic hypocalcemia. The two most feared complications of bisphosphonate use are acute renal failure and osteonecrosis of the jaw (ONJ).</Para>
            <Para TextBreak="No">Renal toxicity has been observed to range in severity from a transient asymptomatic creatinine elevation to permanent dialysis dependence. In one early series, patients who developed renal failure during bisphosphonate treatment underwent kidney biopsies, which showed evidence of acute tubular necrosis with tubular cell degeneration, loss of brush border, and apoptosis [<CitationRef CitationID="CR30_24">30</CitationRef>]. In another series of 72 cases of FDA-reported adverse events with the 4 mg/15 min infusion combination, the effected patients began with a mean baseline creatinine of 1.7 mg/dL (range 0.6–5.2) and developed renal failure an average of 56 days after initiation of zoledronic acid use (range: 1–51 months) [<CitationRef CitationID="CR31_24">31</CitationRef>]. Among patients who developed renal failure, about one-quarter experienced the deterioration of renal function after the first dose.</Para>
            <Para TextBreak="No">The zoledronic acid package insert specifies that single doses should not exceed 4 mg and that the infusion duration should be no less than 15 min. It also recommends that if the baseline creatinine was normal but increased 0.5 mg/dL or was abnormal and increased 1.0 mg/dL within 2 weeks of zoledronic acid dosing, the drug should be held until creatinine is within 10% of its initial value. The most recent update of the document includes recommended starting dose reductions for calculated creatinine clearances of less than 60 mL/min [<CitationRef CitationID="CR32_24">32</CitationRef>].</Para>
            <Para TextBreak="No">ONJ presents clinically in bisphosphonate-treated patients as nonhealing areas of exposed and necrotic bone in the maxillofacial region. Much descriptive literature has been published since the first recognized cases of ONJ in 2003 and 2004 [<CitationRef CitationID="CR33_24">33</CitationRef>, <CitationRef CitationID="CR34_24">34</CitationRef>]. It is exceedingly rare with the use of oral bisphosphonates (e.g., 0.7/100,000 person/years of exposure for alendronate according to Merck [<CitationRef CitationID="CR35_24">35</CitationRef>]). Published retrospective studies of ONJ incidence with intravenous bisphosphonates show estimates ranging from 0.8 to 12% [<CitationRef CitationID="CR36_24">36</CitationRef>]. Another large retrospective analysis of patients treated with intravenous bisphosphonates showed that dose and duration of treatment were higher in patients with ONJ (<Emphasis Type="Italic">P</Emphasis>&lt; 0.0001). Finally, multivariate Cox proportional hazards regression analysis has showed dental extractions (<Emphasis Type="Italic">P</Emphasis> &lt; 0.0001) and treatment with zoledronic acid (<Emphasis Type="Italic">P</Emphasis> = 0.0004) to be significant risk factors for ONJ [<CitationRef CitationID="CR37_24">37</CitationRef>].</Para>
            <Para TextBreak="No">The optimal duration of bisphosphonate therapy in patients with bone metastases from prostate cancer has not yet been defined. Relevant clinical trials have included up to 24 months of treatment. Practice guidelines for duration of therapy for prostate cancer do not yet exist.</Para>
            <Para TextBreak="No">The American Association of Oral and Maxillofacial Surgeons wrote a position paper about bisphosphonate-related ONJ [<CitationRef CitationID="CR35_24">35</CitationRef>]. It recommends oral examination and optimization prior to initiation of treatment (with extraction of nonrestorable teeth and 14–21 day wait until the extraction site has mucosalized), discontinuation of therapy for 3 months on either side of elective dental surgery, and avoidance of invasive procedures if possible. In patients with established ONJ, treatment depends on severity of the lesion. Early lesions seem to benefit from oral antimicrobial rinses such as chlorhexidine 0.12%. Intermediate disease is managed with the addition of systemic antibiotic therapy. Advanced disease usually causes pain and is managed with surgical debridement and antibiotic therapy. Others have suggested that resolution with antibiotic therapy alone is rare and that early conservative surgical therapies such as laser treatment may be more broadly indicated [<CitationRef CitationID="CR38_24">38</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec10">
            <Heading>Future Directions in Bone-Targeted Therapy for Prostate Cancer</Heading>
            <Para TextBreak="No">Though zoledronic acid is the only drug currently approved for the management of prostate cancer bone metastases, there are a variety of nonbisphosphonate bone-targeted drugs currently in development. The two that are in phase III study are the monoclonal antibody RANK-ligand inhibitor denosumab.</Para>
          </Section1>
          <Section1 ID="Sec11">
            <Heading>Denosumab: RANK-Ligand Inhibitor in Current Clinical Trials</Heading>
            <Para TextBreak="No">The role of receptor activator of nuclear factor-kappa-B ligand (RANKL) in osteoclast differentiation, function, and survival makes it a rational target for drug development in osteoclast-mediated diseases. Denosumab is a fully human monoclonal antibody against RANKL and has shown promise in early clinical trials for both benign and malignant bone disease. It is administered subcutaneously and inhibits RANKL by binding avidly and specifically to it. Even a single dose has been shown to promptly decrease the bone turnover marker NTx in 84% of patients and for up to 6 months [<CitationRef CitationID="CR5_24">5</CitationRef>]. In an early trial of denosumab in myeloma and breast cancer patients, the highest two doses suppressed NTx levels within 1 day and sustained this suppression for 84 days. Mean denosumab half-lives were 33.3 and 46.3 days for those two highest doses [<CitationRef CitationID="CR39_24">39</CitationRef>].</Para>
            <Para TextBreak="No">Denosumab has preliminarily been shown to be effective in the treatment of postmenopausal bone loss and in the treatment of bone lesions caused by breast cancer or multiple myeloma. It is currently under development for three distinct indications in the management of prostate cancer: prevention of bone loss and fractures during ADT (discussed in the following section), prevention of bone metastases in castration-resistant prostate cancer, and prevention of SREs in castration-resistant prostate cancer with bone metastases. Over 4,500 patients are involved in these three clinical trials (see Table <InternalRef RefID="Tab2">24.2</InternalRef>).</Para>
            <Para TextBreak="No">Amgen protocol 147 is enrolling men with prostate cancer and rising PSA despite ADT but without bone metastases. The study involves only subjects at high risk for the development of bone metastases based on PSA ≥8 ng/dL and/or PSA doubling time ≤10 months. Subjects are randomized to denosumab or placebo. The study is planned to accrue 1,400 patients. The primary study endpoint is bone metastasis-free survival.</Para>
            <Para TextBreak="No">Amgen protocol 103 is a study of men with prostate cancer metastatic to bone and disease progression despite ADT. Subjects are assigned to denosumab or zoledronic acid, the current standard therapy for prevention of skeletal complications in this setting. The primary endpoint is time to first SRE (pathological fracture, radiation to bone, surgery to bone, or spinal cord compression). The study is planned to accrue 1,700 patients and is designed to demonstrate that denosumab is not inferior to zoledronic acid.</Para>
            <Para TextBreak="No">Denosumab seems to hold much promise in the treatment of prostate cancer, though it requires further evaluation of both efficacy and toxicity. In contrast to zoledronic acid, denosumab has not been associated with renal toxicity or ONJ. Ongoing and future clinical trials will define the efficacy and safety of denosumab.</Para>
          </Section1>
          <Section1 ID="Sec12">
            <Heading>Prevention of Osteoporosis and Fractures During ADT</Heading>
            <Para TextBreak="No">Fractures are a substantial burden to men worldwide [<CitationRef CitationID="CR40_24">40</CitationRef>]. For example, one-third of all hip fractures occur in men [<CitationRef CitationID="CR41_24">41</CitationRef>]. The most common causes of acquired osteoporosis in men are hypogonadism, chronic glucocorticoid therapy, and alcohol abuse [<CitationRef CitationID="CR43_24">42</CitationRef>]. The leading cause of hypogonadism in men is ADT for prostate cancer.</Para>
            <Para TextBreak="No">ADT is the mainstay of treatment for metastatic prostate cancer [<CitationRef CitationID="CR44_24">43</CitationRef>] and is accomplished by either bilateral orchiectomies or by administration of a GnRH agonist. GnRH agonist therapy is also often given to men concurrently with primary radiation for locally advanced disease and to men with recurrent nonmetastatic prostate cancer. BMD falls during ADT, a change that correlates with rising fracture risk [<CitationRef CitationID="CR45_24">44</CitationRef>]. ADT increases the risk for fractures in men [<CitationRef CitationID="CR12_24">12</CitationRef>, <CitationRef CitationID="CR13_24">13</CitationRef>].</Para>
            <Para TextBreak="No">Several bisphosphonates have been shown to increase BMD and decrease markers of bone metabolism in men receiving ADT for prostate cancer. Among these are pamidronate [<CitationRef CitationID="CR46_24">45</CitationRef>, <CitationRef CitationID="CR47_24">46</CitationRef>], zoledronic acid [<CitationRef CitationID="CR48_24">47</CitationRef>, <CitationRef CitationID="CR49_24">48</CitationRef>], and alendronate [<CitationRef CitationID="CR50_24">49</CitationRef>]. Several additional classes of drugs have been studied or are currently under study. Raloxifene and toremifene, both selective estrogen receptor modulators, have been shown to increase BMD and decrease markers of bone metabolism in men receiving ADT for prostate cancer [<CitationRef CitationID="CR51_24">50</CitationRef>, <CitationRef CitationID="CR52_24">51</CitationRef>].</Para>
            <Para TextBreak="No">Until recently, however, there was limited data about the prevention of osteoporotic fractures in men receiving ADT for prostate cancer. Phase III trials to assess the impact of toremifene and denosumab on BMD and incident fractures have been completed. Final results are pending. Denosumab is being studied (Amgen protocol 138) in men with prostate cancer who are receiving current ADT and are at increased risk for fracture based on older age and/or low BMD. Subjects are randomized to denosumab or placebo. The study has accrued 1,468 patients. Study endpoints are incident fractures and change in BMD.</Para>
            <Para TextBreak="No">Toremifene, the selective estrogen receptor modulator, is being studied in a multicenter phase III fracture prevention study in which men 50 years or older are randomized to receive 80 mg daily oral toremifene or placebo. The trial has enrolled 1,392 men and is powered to examine fracture prevention. Planned interim analysis of the first 197 subjects showed that the treatment arm enjoyed significant increases in BMD at all examined skeletal sites [<CitationRef CitationID="CR53_24">52</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec13" Type="Conclusion">
            <Heading>Conclusion</Heading>
            <Para TextBreak="No">Bone metastases are a common feature of advanced prostate cancer. They contribute significantly to the clinical burden of the disease as they frequently cause pain and can also cause fractures and spinal cord compression. Bisphosphonates were the first class of drugs to gain FDA approval for the management of bone metastases. Specifically, zoledronic acid is the standard-of-care for the prevention of SREs due to bone metastases in castration-resistant prostate cancer. The role of bisphosphonates in the management of nonmetastatic disease or androgen-sensitive metastatic disease is currently under study. Bisphosphonates are generally well tolerated but do cause risk for a variety of side effects both common (self-limited acute phase reaction) and rare-but-morbid (ONJ, acute renal failure). Two bone-targeted investigational agents are currently in phase III clinical trials. Denosumab, a human monoclonal antibody targeting RANKL, is under study in three distinct clinical trials for the prevention of bone loss and fractures during ADT, the prevention of bone metastases in castration-resistant prostate cancer, and the prevention of SREs in castration-resistant prostate cancer with bone metastases.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_24.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_24">
              <CitationNumber>1</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WJ</Initials>
                  <FamilyName>Boyle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WS</Initials>
                  <FamilyName>Simonet</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Lacey</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Osteoclast differentiation and activation</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>423</VolumeID>
                <IssueID>6937</IssueID>
                <FirstPage>337</FirstPage>
                <LastPage>42</LastPage>
                <Occurrence Type="PID">
                  <Handle>12748652</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nature01658</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXjs1ynu7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423(6937):337–42.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_24">
              <CitationNumber>2</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NW</Initials>
                  <FamilyName>Clarke</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>McClure</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NJ</Initials>
                  <FamilyName>George</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Osteoblast function and osteomalacia in metastatic prostate cancer</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>24</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>286</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>8375452</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3szoslertw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Clarke NW, McClure J, George NJ. Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol 1993;24(2):286–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_24">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LM</Initials>
                  <FamilyName>Demers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Costa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Lipton</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Biochemical markers and skeletal metastases</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>88</VolumeID>
                <IssueID>12 Suppl</IssueID>
                <FirstPage>2919</FirstPage>
                <LastPage>26</LastPage>
                <Occurrence Type="PID">
                  <Handle>10898335</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0142(20000615)88:12+&lt;2919::AID-CNCR7&gt;3.0.CO;2-Z</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXksVCmsL4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer 2000;88(12 Suppl):2919–26.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_24">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Cook</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Coleman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Brown</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>11 Pt 1</IssueID>
                <FirstPage>3361</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>16740758</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-06-0269</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XltFyis78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cook RJ, Coleman R, Brown J, et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006;12(11 Pt 1):3361–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_24">
              <CitationNumber>5</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Bekker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Holloway</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AS</Initials>
                  <FamilyName>Rasmussen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women</ArticleTitle>
                <JournalTitle>J Bone Miner Res</JournalTitle>
                <VolumeID>19</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>1059</FirstPage>
                <LastPage>66</LastPage>
                <Occurrence Type="PID">
                  <Handle>15176987</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1359/JBMR.040305</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXlvFWrtr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19(7):1059–66.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_24">
              <CitationNumber>6</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JF</Initials>
                  <FamilyName>Maillefert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Sibilia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Michel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Saussine</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RM</Initials>
                  <FamilyName>Javier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Tavernier</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>161</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>1219</FirstPage>
                <LastPage>22</LastPage>
                <Occurrence Type="PID">
                  <Handle>10081873</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(01)61639-2</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXitVers70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999;161(4):1219–22.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_24">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FJ</Initials>
                  <FamilyName>McGovern</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AL</Initials>
                  <FamilyName>Zietman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>345</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>948</FirstPage>
                <LastPage>55</LastPage>
                <Occurrence Type="PID">
                  <Handle>11575286</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa010845</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXntlehtbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345(13):948–55.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_24">
              <CitationNumber>8</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Berruti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Dogliotti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Terrone</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>167</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>2361</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>11992038</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(05)64985-3</Handle>
                </Occurrence>
                <BibComments>discussion 7</BibComments>
              </BibArticle>
              <BibUnstructured>Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray asbsorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002;167(6):2361–7; discussion 7.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_24">
              <CitationNumber>9</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HW</Initials>
                  <FamilyName>Daniell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SR</Initials>
                  <FamilyName>Dunn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DW</Initials>
                  <FamilyName>Ferguson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Lomas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Niazi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PT</Initials>
                  <FamilyName>Stratte</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Progressive osteoporosis during androgen deprivation therapy for prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>163</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>181</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>10604342</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(05)68000-7</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3c%2Fmslygsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000;163(1):181–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_24">
              <CitationNumber>10</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Diamond</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Campbell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Bryant</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Lynch</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>83</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>1561</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>9781950</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/(SICI)1097-0142(19981015)83:8&lt;1561::AID-CNCR11&gt;3.0.CO;2-Z</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXntVeju7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998;83(8):1561–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_24">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Eastham</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Gleason</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Shasha</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Tchekmedyian</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Zinner</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>169</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>2008</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>12771706</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/01.ju.0000063820.94994.95</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXktlOis7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169(6):2008–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_24">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>VB</Initials>
                  <FamilyName>Shahinian</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YF</Initials>
                  <FamilyName>Kuo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Freeman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JS</Initials>
                  <FamilyName>Goodwin</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Risk of fracture after androgen deprivation for prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>352</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>154</FirstPage>
                <LastPage>64</LastPage>
                <Occurrence Type="PID">
                  <Handle>15647578</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa041943</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXksFajuw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352(2):154–64.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_24">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WC</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Brandman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Q</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Botteman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Pashos</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <IssueID>31</IssueID>
                <FirstPage>7897</FirstPage>
                <LastPage>903</LastPage>
                <Occurrence Type="PID">
                  <Handle>16258089</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2004.00.6908</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXht1Cqs7fI</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005;23(31):7897–903.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_24">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Boyce</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Moyneur</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Duh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MK</Initials>
                  <FamilyName>Raut</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Brandman</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>175</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>136</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16406890</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(05)00033-9</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XntlWktw%3D%3D</Handle>
                </Occurrence>
                <BibComments>discussion 9</BibComments>
              </BibArticle>
              <BibUnstructured>Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006;175(1):136–9; discussion 9.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_24">
              <CitationNumber>15</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Strum</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>McDermed</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Scholz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Johnson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Tisman</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade</ArticleTitle>
                <JournalTitle>Br J Urol</JournalTitle>
                <VolumeID>79</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>933</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>9202563</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1046/j.1464-410X.1997.00234.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXksVKitr4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997;79(6):933–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_24">
              <CitationNumber>16</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Santini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>U</Initials>
                  <FamilyName>Vespasiani Gentilucci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Vincenzi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">The antineoplastic role of bisphosphonates: from basic research to clinical evidence</ArticleTitle>
                <JournalTitle>Ann Oncol</JournalTitle>
                <VolumeID>14</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>1468</FirstPage>
                <LastPage>76</LastPage>
                <Occurrence Type="PID">
                  <Handle>14504045</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/annonc/mdg401</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3svktlKjsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Santini D, Vespasiani Gentilucci U, Vincenzi B, et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003;14(10):1468–76.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_24">
              <CitationNumber>17</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Fisher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Rogers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Halasy</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>96</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>133</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>9874784</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.96.1.133</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXjvV2isA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 1999;96(1):133–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_24">
              <CitationNumber>18</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RG</Initials>
                  <FamilyName>Russell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Xia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Dunford</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy</ArticleTitle>
                <JournalTitle>Ann N Y Acad Sci</JournalTitle>
                <VolumeID>1117</VolumeID>
                <FirstPage>209</FirstPage>
                <LastPage>57</LastPage>
                <Occurrence Type="PID">
                  <Handle>18056045</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1196/annals.1402.089</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhtVGmurY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007;1117:209–57.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_24">
              <CitationNumber>19</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LS</Initials>
                  <FamilyName>Rosen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Gordon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kaminski</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial</ArticleTitle>
                <JournalTitle>Cancer J</JournalTitle>
                <VolumeID>7</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>377</FirstPage>
                <LastPage>87</LastPage>
                <Occurrence Type="PID">
                  <Handle>11693896</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3Mnjs1yqtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7(5):377–87.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_24">
              <CitationNumber>20</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LS</Initials>
                  <FamilyName>Rosen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Gordon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Tchekmedyian</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial–the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>21</VolumeID>
                <IssueID>16</IssueID>
                <FirstPage>3150</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>12915606</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2003.04.105</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpsVWqtb0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial–the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21(16):3150–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_24">
              <CitationNumber>21</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Saad</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Gleason</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Murray</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>94</VolumeID>
                <IssueID>19</IssueID>
                <FirstPage>1458</FirstPage>
                <LastPage>68</LastPage>
                <Occurrence Type="PID">
                  <Handle>12359855</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/94.19.1458</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XosVans7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458–68.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_24">
              <CitationNumber>22</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Saad</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Gleason</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Murray</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>96</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>879</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>15173273</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/djh141</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXkvVSrurk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96(11):879–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_24">
              <CitationNumber>23</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Small</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JJ</Initials>
                  <FamilyName>Seaman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Petrone</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MO</Initials>
                  <FamilyName>Kowalski</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>21</VolumeID>
                <IssueID>23</IssueID>
                <FirstPage>4277</FirstPage>
                <LastPage>84</LastPage>
                <Occurrence Type="PID">
                  <Handle>14581438</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2003.05.147</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpsVWqu7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21(23):4277–84.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_24">
              <CitationNumber>24</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DS</Initials>
                  <FamilyName>Ernst</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EW</Initials>
                  <FamilyName>Winquist</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>21</VolumeID>
                <IssueID>17</IssueID>
                <FirstPage>3335</FirstPage>
                <LastPage>42</LastPage>
                <Occurrence Type="PID">
                  <Handle>12947070</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2003.03.042</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXps1akurk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ernst DS, Tannock IF, Winquist EW, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003;21(17):3335–42.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_24">
              <CitationNumber>25</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Dearnaley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Sydes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MD</Initials>
                  <FamilyName>Mason</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>95</VolumeID>
                <IssueID>17</IssueID>
                <FirstPage>1300</FirstPage>
                <LastPage>11</LastPage>
                <Occurrence Type="PID">
                  <Handle>12953084</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/djg038</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXntVKhuro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dearnaley DP, Sydes MR, Mason MD, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003;95(17):1300–11.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_24">
              <CitationNumber>26</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MD</Initials>
                  <FamilyName>Mason</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Sydes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Glaholm</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Oral sodium clodronate for nonmetastatic prostate cancer–results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>99</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>765</FirstPage>
                <LastPage>76</LastPage>
                <Occurrence Type="PID">
                  <Handle>17505072</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/djk178</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXnt1ags70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mason MD, Sydes MR, Glaholm J, et al. Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007;99(10):765–76.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_24">
              <CitationNumber>27</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Kabbinavar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Saad</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>2918</FirstPage>
                <LastPage>25</LastPage>
                <Occurrence Type="PID">
                  <Handle>15860850</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2005.01.529</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005;23(13):2918–25.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_24">
              <CitationNumber>28</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PP</Initials>
                  <FamilyName>Major</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Cook</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BL</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Zheng</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic Acid in patients with bone metastases from solid tumors</ArticleTitle>
                <JournalTitle>Support Cancer Ther</JournalTitle>
                <VolumeID>2</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>234</FirstPage>
                <LastPage>40</LastPage>
                <Occurrence Type="PID">
                  <Handle>18628179</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.3816/SCT.2005.n.017</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Major PP, Cook RJ, Chen BL, Zheng M. Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic Acid in patients with bone metastases from solid tumors. Support Cancer Ther 2005;2(4):234–40.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_24">
              <CitationNumber>29</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Zojer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Keck</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Pecherstorfer</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Comparative tolerability of drug therapies for hypercalcaemia of malignancy</ArticleTitle>
                <JournalTitle>Drug Saf</JournalTitle>
                <VolumeID>21</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>389</FirstPage>
                <LastPage>406</LastPage>
                <Occurrence Type="PID">
                  <Handle>10554053</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.2165/00002018-199921050-00004</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXnsFWgurw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999;21(5):389–406.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_24">
              <CitationNumber>30</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GS</Initials>
                  <FamilyName>Markowitz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PL</Initials>
                  <FamilyName>Fine</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JI</Initials>
                  <FamilyName>Stack</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Toxic acute tubular necrosis following treatment with zoledronate (Zometa)</ArticleTitle>
                <JournalTitle>Kidney Int</JournalTitle>
                <VolumeID>64</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>281</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>12787420</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1046/j.1523-1755.2003.00071.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXlsFeks74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64(1):281–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_24">
              <CitationNumber>31</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JT</Initials>
                  <FamilyName>Chang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Green</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Beitz</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Renal failure with the use of zoledronic acid</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>349</VolumeID>
                <IssueID>17</IssueID>
                <FirstPage>1676</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>14573746</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJM200310233491721</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXosFakurw%3D</Handle>
                </Occurrence>
                <BibComments>discussion 9</BibComments>
              </BibArticle>
              <BibUnstructured>Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349(17):1676–9; discussion 9.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_24">
              <CitationNumber>32</CitationNumber>
              <BibUnstructured>Zometa. Full prescribing information. Novartis Pharmaceuti-cals Corporation. Rev: October 2009.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_24">
              <CitationNumber>33</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Marx</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic</ArticleTitle>
                <JournalTitle>J Oral Maxillofac Surg</JournalTitle>
                <VolumeID>61</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>1115</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>12966493</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0278-2391(03)00720-1</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61(9):1115–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_24">
              <CitationNumber>34</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Ruggiero</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Mehrotra</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TJ</Initials>
                  <FamilyName>Rosenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Engroff</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases</ArticleTitle>
                <JournalTitle>J Oral Maxillofac Surg</JournalTitle>
                <VolumeID>62</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>527</FirstPage>
                <LastPage>34</LastPage>
                <Occurrence Type="PID">
                  <Handle>15122554</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.joms.2004.02.004</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62(5):527–34.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_24">
              <CitationNumber>35</CitationNumber>
              <BibArticle>
                <InstitutionalAuthorName>Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons</InstitutionalAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws</ArticleTitle>
                <JournalTitle>J Oral Maxillofac Surg</JournalTitle>
                <VolumeID>65</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>369</FirstPage>
                <LastPage>76</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.joms.2006.11.003</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65(3):369–76.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_24">
              <CitationNumber>36</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EP</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LB</Initials>
                  <FamilyName>Kaban</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Strewler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Raje</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Troulis</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy</ArticleTitle>
                <JournalTitle>J Oral Maxillofac Surg</JournalTitle>
                <VolumeID>65</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>1328</FirstPage>
                <LastPage>31</LastPage>
                <Occurrence Type="PID">
                  <Handle>17577497</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.joms.2007.03.006</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007;65(7):1328–31.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_24">
              <CitationNumber>37</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AO</Initials>
                  <FamilyName>Hoff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BB</Initials>
                  <FamilyName>Toth</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Altundag</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates</ArticleTitle>
                <JournalTitle>J Bone Miner Res</JournalTitle>
                <VolumeID>23</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>826</FirstPage>
                <LastPage>36</LastPage>
                <Occurrence Type="PID">
                  <Handle>18558816</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1359/jbmr.080205</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXnvVGjs70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23(6):826–36.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_24">
              <CitationNumber>38</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Vescovi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Manfredi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Merigo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Meleti</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Early surgical approach preferable to medical therapy for bisphosphonate-related osteonecrosis of the jaws</ArticleTitle>
                <JournalTitle>J Oral Maxillofac Surg</JournalTitle>
                <VolumeID>66</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>831</FirstPage>
                <LastPage>2</LastPage>
                <Occurrence Type="PID">
                  <Handle>18355616</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.joms.2007.11.025</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Vescovi P, Manfredi M, Merigo E, Meleti M. Early surgical approach preferable to medical therapy for bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2008;66(4):831–2.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_24">
              <CitationNumber>39</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JJ</Initials>
                  <FamilyName>Body</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Facon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Coleman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>1221</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>16489077</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-05-1933</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhsFaltLg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12(4):1221–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_24">
              <CitationNumber>40</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PR</Initials>
                  <FamilyName>Ebeling</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Clinical practice. Osteoporosis in men</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>358</VolumeID>
                <IssueID>14</IssueID>
                <FirstPage>1474</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>18385499</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMcp0707217</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXktlSgt7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med 2008;358(14):1474–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_24">
              <CitationNumber>41</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Seeman</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">The structural basis of bone fragility in men</ArticleTitle>
                <JournalTitle>Bone</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>143</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>10423041</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S8756-3282(99)00117-9</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1MzkvF2jtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Seeman E. The structural basis of bone fragility in men. Bone 1999;25(1):143–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_24">
              <CitationNumber>42</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Bilezikian</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Osteoporosis in men</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>84</VolumeID>
                <IssueID>10</IssueID>
                <FirstPage>3431</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>10522975</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/jc.84.10.3431</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXms1Ohsbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bilezikian JP. Osteoporosis in men. J Clin Endocrinol Metab 1999;84(10):3431–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_24">
              <CitationNumber>43</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Sharifi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WL</Initials>
                  <FamilyName>Dahut</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Androgen deprivation therapy for prostate cancer</ArticleTitle>
                <JournalTitle>JAMA</JournalTitle>
                <VolumeID>294</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>238</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>16014598</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1001/jama.294.2.238</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXmtlSlt7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294(2):238–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_24">
              <CitationNumber>44</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Greenspan</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Approach to the prostate cancer patient with bone disease</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>93</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>2</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>18178905</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/jc.2007-1402</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXnsVOrtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Greenspan SL. Approach to the prostate cancer patient with bone disease. J Clin Endocrinol Metab 2008;93(1):2–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_24">
              <CitationNumber>45</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FJ</Initials>
                  <FamilyName>McGovern</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AL</Initials>
                  <FamilyName>Zietman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>345</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>948</FirstPage>
                <LastPage>55</LastPage>
                <Occurrence Type="PID">
                  <Handle>11575286</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa010845</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXntlehtbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N Engl J Med 2001;345(13):948–55.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_24">
              <CitationNumber>46</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TH</Initials>
                  <FamilyName>Diamond</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Winters</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>92</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>1444</FirstPage>
                <LastPage>50</LastPage>
                <Occurrence Type="PID">
                  <Handle>11745221</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0142(20010915)92:6&lt;1444::AID-CNCR1468&gt;3.0.CO;2-M</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXnvVygsr4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Diamond TH, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001;92(6):1444–50.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_24">
              <CitationNumber>47</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Eastham</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Gleason</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Shasha</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Tchekmedyian</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Zinner</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>169</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>2008</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>12771706</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/01.ju.0000063820.94994.95</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXktlOis7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith MR, Eastham J, Gleason D, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169(6):2008–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_24">
              <CitationNumber>48</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MD</Initials>
                  <FamilyName>Michaelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DS</Initials>
                  <FamilyName>Kaufman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>1038</FirstPage>
                <LastPage>42</LastPage>
                <Occurrence Type="PID">
                  <Handle>17369566</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2006.07.3361</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXksVyrs74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007;25(9):1038–42.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_24">
              <CitationNumber>49</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Greenspan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Trump</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NM</Initials>
                  <FamilyName>Resnick</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial</ArticleTitle>
                <JournalTitle>Ann Intern Med</JournalTitle>
                <VolumeID>146</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>416</FirstPage>
                <LastPage>24</LastPage>
                <Occurrence Type="PID">
                  <Handle>17371886</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.7326/0003-4819-146-6-200703200-00006</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007;146(6):416–24.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_24">
              <CitationNumber>50</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Fallon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JS</Initials>
                  <FamilyName>Finkelstein</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>89</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>3841</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>15292315</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/jc.2003-032058</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXmslKmtLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004;89(8):3841–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_24">
              <CitationNumber>51</CitationNumber>
              <BibUnstructured>Steiner MS, Patterson A, Israeli R, Barnette KG, Boger R, Price D. Toremifene citrate versus placebo for treatment of bone loss and other complications of androgen deprivation therapy in patients with prostate cancer. Proc ASCO (abstract 4597) 2004.</BibUnstructured>
            </Citation>
            <Citation ID="CR53_24">
              <CitationNumber>52</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Malkowicz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Chu</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>179</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>152</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>18001802</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.juro.2007.08.137</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD2sjjvVWrsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008;179(1):152–5.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
